Efficacy and Safety of Zerafil ® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

Conditions:   Allergic Asthma;   Uncontrolled Moderate to Severe Interventions:   Biological: Omalizumab (CinnaGen);   Biological: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) Sponsor:   Cinnagen Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials